Beigene (NASDAQ:ONC) Shares Gap Down - What's Next?

Beigene, Ltd. (NASDAQ:ONC - Get Free Report) gapped down prior to trading on Monday . The stock had previously closed at $269.63, but opened at $263.85. Beigene shares last traded at $265.44, with a volume of 21,285 shares.

Wall Street Analyst Weigh In

A number of equities analysts have commented on ONC shares. Royal Bank of Canada dropped their target price on shares of Beigene from $312.00 to $311.00 and set an "outperform" rating on the stock in a research note on Thursday, May 8th. JMP Securities set a $348.00 price target on Beigene in a research note on Friday, February 28th. JPMorgan Chase & Co. boosted their price objective on shares of Beigene from $311.00 to $317.00 and gave the company an "overweight" rating in a report on Monday, April 21st. Bank of America raised shares of Beigene from a "neutral" rating to a "buy" rating and raised their price target for the stock from $207.00 to $320.00 in a research report on Monday, March 3rd. Finally, TD Securities restated a "buy" rating and issued a $334.00 target price on shares of Beigene in a research note on Thursday, April 24th. Seven research analysts have rated the stock with a buy rating, According to MarketBeat.com, Beigene currently has an average rating of "Buy" and a consensus target price of $319.00.

Beigene Trading Down 1.7%

The stock has a fifty day moving average price of $241.38. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.93 and a quick ratio of 1.72. The stock has a market cap of $29.01 billion, a P/E ratio of -32.15, a price-to-earnings-growth ratio of 7.73 and a beta of 0.30.

Beigene (NASDAQ:ONC - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The company reported $1.22 EPS for the quarter, topping the consensus estimate of ($0.71) by $1.93. The firm had revenue of $1.12 billion during the quarter, compared to analysts' expectations of $1.12 billion. Beigene had a negative return on equity of 25.12% and a negative net margin of 25.94%. As a group, equities research analysts expect that Beigene, Ltd. will post -5.82 EPS for the current year.

Insider Activity at Beigene

In other news, insider Xiaodong Wang sold 41,760 shares of the firm's stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $261.28, for a total transaction of $10,911,052.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Titus B. Ball sold 134 shares of Beigene stock in a transaction that occurred on Wednesday, June 11th. The shares were sold at an average price of $258.36, for a total transaction of $34,620.24. The disclosure for this sale can be found here. In the last quarter, insiders sold 228,258 shares of company stock valued at $58,317,119. Corporate insiders own 6.62% of the company's stock.

Beigene Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.